Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.53 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.53 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27463271 | 0.90 | DPP4 (0.81) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL3070677 | 0.86 | TDP1 (0.89) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL5991486 | 0.85 | DPP4 (0.73) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL8559822 | 0.84 | TDP1 (0.85) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL9242650 | 0.84 | TDP1 (0.85) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL7426101 | 0.84 | TDP1 (0.85) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL5993545 | 0.84 | DPP4 (0.71) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL8894978 | 0.84 | MAPT (0.74) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL7704524 | 0.82 | DPP4 (0.69) | DPP4TDP1NPC1RAB9ACASP3 | |
| SCHEMBL8896277 | 0.81 | TDP1 (0.79) | DPP4TDP1NPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270499-A1 | Use for 2-amino-2-propane-1, 3-diols | WELSCH CAROLE | 2007-11-22 | — | — | US | claimed |
| US-20040214897-A1 | Uses for 2-amino-2-propane-1,3-diols | WELSCH CAROLE | 2004-10-28 | — | — | US | claimed |
| WO-2003009836-A2 | NEW USES FOR 2-AMINO-2-PROPANE-1,3-DIOLS | NOVARTIS AG (CH) | 2003-02-06 | — | — | WO | claimed |
| CN-110548011-A | Pharmaceutical compositions comprising S1P modulators | NOVARTIS AG | 2019-12-10 | — | — | CN | disclosed |
| EP-3103448-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN S1P MODULATOR | NOVARTIS AG (CH) | 2016-12-14 | — | — | EP | disclosed |
| US-20160338978-A1 | Organic Compounds | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| CN-105012266-A | Pharmaceutical compositions comprising S1P receptor | NOVARTIS AG | 2015-11-04 | — | — | CN | disclosed |
| US-20140227358-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-20120288559-A1 | ORGANIC COMPOUNDS | AMBUEHL MICHAEL (US) | 2012-11-15 | — | — | US | disclosed |
| US-20100040678-A1 | ORGANIC COMPOUNDS | AMBUHL MICHAEL | 2010-02-18 | — | — | US | disclosed |
| CN-101516345-A | Pharmaceutical compositions comprising S1P modulators | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| WO-2008037421-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN S1P MODULATOR | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| EP-1905434-A1 | Organic compounds comprising an S1P receptor agonist and their therapeutic use | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070270499-A1 | Use for 2-amino-2-propane-1, 3-diols | WELSCH CAROLE | 2007-11-22 | — | — | US | disclosed |
| CN-1290819-C | 2-aminopropane-1,3-glycol compound, its use as medicine and its synthetic intermediate | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2006-12-20 | — | — | CN | disclosed |
| US-20040214897-A1 | Uses for 2-amino-2-propane-1,3-diols | WELSCH CAROLE | 2004-10-28 | — | — | US | disclosed |
| CN-1480450-A | 2-aminopropane-1,3-glycol compound, its use as medicine and its synthetic intermediate | ������ҩ��ʽ���� | 2004-03-10 | — | — | CN | disclosed |
| CN-1137086-C | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | ������ҩ��ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| WO-2003009836-A2 | NEW USES FOR 2-AMINO-2-PROPANE-1,3-DIOLS | NOVARTIS AG (CH) | 2003-02-06 | — | — | WO | disclosed |
| CN-1259117-A | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338978-A1 | Organic Compounds | S1PR1, S1PR4, S1PR3 | DPP4 1542/4885TDP1 3109/4885NPC1 319/4885 |
| US-20140227358-A1 | ORGANIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | DPP4 1686/4885TDP1 2821/4885NPC1 405/4885 |
| US-20040214897-A1 | Uses for 2-amino-2-propane-1,3-diols | DGKB, GLS2, GLS | DPP4 3386/4885TDP1 2176/4885NPC1 2912/4885 |
| US-20070270499-A1 | Use for 2-amino-2-propane-1, 3-diols | DGKB, GLS2, GLS | DPP4 3612/4885TDP1 2253/4885NPC1 2781/4885 |
| US-20120288559-A1 | ORGANIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | DPP4 1686/4885TDP1 2821/4885NPC1 405/4885 |
| US-20100040678-A1 | ORGANIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | DPP4 1686/4885TDP1 2821/4885NPC1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.